TrialNature communications2026

Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial.

Rebecca J Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.